Pathogenics Announces Data Demonstrating Novel Anti-Infective/Anti-Inflammatory Medicine Kills COVID-19 Virus

  • In Vitro Data Shows NCT Kills SARS-CoV-2 (COVID-19 Virus), Respiratory Syncytial Virus (RSV), and Influenza A Virus
  • NCT was Able to Rapidly Kill Viruses Within 1 to 10 Minutes Absent Cytotoxicity of Inactivated NCT

NCT Interview: Anti-COVID Therapies – New Research and Mechanisms of Action


OPKO Health & Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection

  • In Vitro Data Shows OPKO’s Formulation of NCT Has Promising Activity Against Acanthamoeba Keratitis, a Serious Ocular Infection
  • Provides Additional Evidence That This Phase II Agent Has Good Tolerability and Broad Anti-Microbial Activity Against a Wide Range of Pathogens

Acuity Pharmaceuticals & Pathogenics Announce Preclinical Data Demonstrating Utility of NCT in Viral Conjunctivitis

  • New Published Data Show Proprietary Formulation of NCT Has Promising Activity in An Animal Model of This Common Opthalmic Infection That Has No Approved Therapies

Pathogenics Inc. Licenses Worldwide Rights To Novel Anti-infective Compound for Ophthalmological Use